MagSense HER2
Phase 1- Indications
- HER2-positive breast cancer
Company intelligence / Profile preview
Imagion Biosystems has completed a multi-site Phase I study of its MagSense® HER2 imaging agent for non-invasive detection of lymph node metastasis in breast cancer. The company has begun manufacturing the agent ahead of a planned Phase II trial. Additional programs targeting ovarian and prostate cancers are at earlier stages. The company’s technology aims to improve early detection and staging of cancers using bio-safe magnetic nanoparticles with standard MRI instruments, without ionizing radiation or radioactive tracers.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Imagion Biosystems.